» Articles » PMID: 3886399

Effects of BAY L 5240, a Fixed Combination of Low Dose Nifedipine and Acebutolol on Hypertension: Comparison with Standard Dose Nifedipine

Overview
Specialty Pharmacology
Date 1985 Jan 1
PMID 3886399
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

116 patients from 4 clinics participated in a double blind study to assess the efficacy of (BAY l 5240), a nifedipine-acebutolol fixed combination (10 mg + 100 mg), as compared to nifedipine 20 mg in essential hypertension. During the 10 week study, the mean recumbent blood pressure decreased 1 to 3 h after treatment from 175.5/105.2 to 148.3/88.0 mmHg in the BAY l 5240 group and from 174.3/102.9 to 150.3/86.5 mmHg in the nifedipine group. The results also showed a comparable decrease in the mean systolic (SBP) and diastolic (DBP) blood pressures before treatment (24 h after last tablet) and after physical exertion before and after either drug given for 4 weeks. Doubling of the dose for 4 additional weeks produced a moderate and similar additional decrease in blood pressure. The results show the possibility of treating essential hypertension with a low dose of a beta-adrenergic blocking agent in combination with 10 mg nifedipine. Both regimens were well tolerated. One patient in the BAY l 5240 group and 2 in the nifedipine group, all treated by the same investigator, were withdrawn from the study because of headache during the nifedipine pre-period.

Citing Articles

Blood pressure lowering effects of β-blockers as add-on or combination therapy: A meta-analysis of randomized controlled trials.

Guo Q, Zhu Z, Feng Y, Lin J, Wang J J Clin Hypertens (Greenwich). 2023; 25(3):227-237.

PMID: 36756690 PMC: 9994166. DOI: 10.1111/jch.14616.


Combination therapy with calcium-entry blockers and beta-adrenoceptor antagonists in hypertension.

Sever P Cardiovasc Drugs Ther. 1989; 3 Suppl 1:327-32.

PMID: 2577298 DOI: 10.1007/BF00148478.


Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Lessem J, Singh B Cardiovasc Drugs Ther. 1989; 3(3):355-73.

PMID: 2577284 DOI: 10.1007/BF01858108.


Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Sorkin E, Clissold S, Brogden R Drugs. 1985; 30(3):182-274.

PMID: 2412780 DOI: 10.2165/00003495-198530030-00002.


Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Kirsten R, Nelson K, Weidinger G, Welzel D Eur J Clin Pharmacol. 1990; 39(5):435-9.

PMID: 2076734 DOI: 10.1007/BF00280932.

References
1.
EKELUND L, Ekelund C, Rossner S . Antihypertensive effects at rest and during exercise of a calcium blocker, nifedipine, alone and in combination with metoprolol. Acta Med Scand. 1982; 212(1-2):71-5. DOI: 10.1111/j.0954-6820.1982.tb03172.x. View

2.
Hallin L, Andren L, Hansson L . Controlled trial of nifedipine and bendroflumethiazide in hypertension. J Cardiovasc Pharmacol. 1983; 5(6):1083-5. DOI: 10.1097/00005344-198311000-00025. View

3.
Husted S, Nielsen H, Christensen C, Lederballe Pedersen O . Long-term therapy of arterial hypertension with nifedipine given alone or in combination with a beta-adrenoceptor blocking agent. Eur J Clin Pharmacol. 1982; 22(2):101-3. DOI: 10.1007/BF00542452. View

4.
OGILVIE R, Hamet P, Kreeft J, Larochelle P . Once-daily dosing of acebutolol in hypertension. J Cardiovasc Pharmacol. 1983; 5(1):157-61. DOI: 10.1097/00005344-198301000-00024. View

5.
Turner A, Brocklehurst J . Comparison of efficacy of a single daily dose of 400 mg acebutolol and 100 mg atenolol in the treatment of arterial hypertension. Curr Med Res Opin. 1983; 8(8):570-6. DOI: 10.1185/03007998309109800. View